Introduction
Several studies showed a close correlation between passively acquired anti-SSA/Ro antibodies and neonatal lupus erythematosus (NLE) syndrome in infants born from mothers with connective tissue disease (CTD). [1] [2] [3] [4] [5] [6] [7] The two major clinical manifestations associated with this condition are congenital complete heart block (CCHB) and cutaneous lupus lesions. 5, 8 Less frequently reported features include cholestatic liver disease and blood cell disorders. 9, 10 In addition, electrocardiographic abnormalities, such as sinus bradycardia and prolongation of the corrected QT (QTc) interval, have been described. [11] [12] [13] [14] [15] Moreover, anti-SSA/Ro-positive pregnant women frequently carry fetuses with Doppler echocardiographic signs of first-degree atrioventricular block (AVB), that show the tendency to revert spontaneously in the majority of fetuses, although in a few cases they may persist until birth. [16] [17] [18] The frequency of these alterations is not yet known.
The aim of our study was to verify the presence of electrocardiographic abnormalities in a group of neonates born from CTD mothers positive for anti-SSA/Ro antibodies during pregnancy, without CCHB at birth: study group. A group of neonates born from mothers with CTD without anti-SSA/Ro antibodies was evaluated as control. Moreover, in these two groups of infants, we compared hematologic parameters and liver and kidney function tests at birth.
Materials and methods

Infants and mothers
This study was performed in a single center, the Spedali CiviliHospital of Brescia, from October 1999 to June 2005. During this period, all children born from mothers with CTD were prospectively enrolled in the study, after a written informed consent was obtained from both parents.
Exclusion criteria were infants with CCHB, and infants born from extractable nuclear antigen (ENA)-positive and anti-SSA/Ro-negative mothers.
All mothers were closely monitored, monthly, during pregnancy. All women with CTD were tested before and during pregnancy for anti-ENA antibodies, including anti-SSA/Ro antibodies and anti-SSB/La antibodies.
A thorough physical examination, including weight, length and head circumference assessment was performed in all infants at birth and at 1, 3, 6 and 12 months of life.
Infants from anti-SSA/Ro-positive mothers (study group) were checked for anti-SSA/Ro antibodies at birth, and if positive, to evaluate the autoantibodies loss were checked again at 12 months of life.
Twenty standard electrocardiograms (ECGs) from five infants of CTD mothers, positive for anti-SSA/Ro antibodies, were also included in a multicenter study that evaluated standard and 24-h ECGs. 19 Identification of antibodies Antibodies to SSA/Ro were determined by counterimmunoelectrophoresis and immunoblotting, using as substrate a human spleen extract prepared according to the method of Clark et al. 20 Antibodies to other extractable nuclear antigens (Sm, U1 RNP, La/SS-B, etc) were detected by counterimmunoelectrophoresis, using as substrate a rabbit thyme extract (Peel-Freeze, Rogers, AR, USA). Samples from mothers and children were examined by the same methods.
Laboratory investigations
Total and differential blood cell counts, liver and renal function tests and electrolytes by standard hematologic and biochemical methods were performed in all babies at birth. In this study, we diagnosed a neutropenia when the absolute neutrophil count was <1500/ml, lymphopenia when absolute lymphocyte count was <1500/ml and thrombocytopenia when platelet count was <150 000/ml. 21, 22 Neonatal anemia was defined when hemoglobin value was two standard deviations below the normal mean value for gestational age and birth weight. 23 ECG studies and analysis Standard 12-lead ECGs were systematically obtained at 4 days, 1, 3, 6 and 12 months of life in study group infants. In control group, ECGs were recorded at birth (4 days) and, if normal, at 12 months of age. Measurement of the PR interval, QT interval and heart rate on all ECGs were performed by a pediatric cardiologist; QT intervals were hand measured and corrected for heart rate (QTc) according to Bazett's formula. If a QTc interval prolongation was observed, ECG was repeated every 2 weeks until normalization. Reference electrocardiographic values were considered those published by Davignon et al. 24, 25 in agreement with the guidelines for the interpretation of the neonatal ECG, by the task force of the European Society of Cardiology.
Statistical analysis
The statistical analysis was performed using unpaired Student t-test or w 2 with Yates correction to evaluate differences of infants' characteristics between the two groups. Relationships were assessed with the Pearson's correlation coefficients; linear regression lines were fitted by the least-squares method. A P-value >0.05 was considered not significant. All computations were performed using a commercial statistical package (STATISTICA for Windows, StatSoft Inc., Tulsa, OK, USA).
Results
During the study period, we observed 107 infants from CTD mothers. One infants, from an anti-SSA/Ro-positive mother, who showed a CCHB at birth, and five infants from mothers with ENA-positive and anti-SSA/Ro-negative antibodies were excluded from the study.
The remaining 101 children were divided into two groups: 51 infants from 51 pregnancies of 43 mothers with CTD and positive for anti-SSA/Ro antibodies (seven of these mothers were also positive for anti-SSB/La antibodies) were included into the study group. Fifty infants from 49 pregnancies (one twin) of 44 mothers with CTD and negative for anti-ENA antibodies were included into the control group.
The characteristics of mothers and infants at birth are reported in Table 1 . No significant differences were observed in the two groups of weight and gestational age, or number of infants who were pre-term or small for gestational age.
Forty-seven of the 51 study group infants were checked for anti-SSA/Ro antibodies at birth; of these, 35 (74.5%) were positive.
The 31 infants who were tested at 12 months were all negative.
During follow-up period, all infants showed normal growth. Two anti-SSA/Ro-positive infants (3.9%) developed a skin rash after exposure to ultraviolet light. Time of detection was 6 and 8 weeks, respectively. Both cases had facial involvement with periorbital distribution; one of these had annular lesions also on the trunk. Both rashes resolved with low-potency topical steroid treatment.
Laboratory investigations at birth
Hematologic parameters are summarized in Table 2 . No case of neutropenia, lymphopenia or anemia, and two cases (3.9%) of thrombocytopenia were observed in the study group infants. The two cases of thrombocytopenia were secondary to maternal-acquired antibodies against nonspecific platelet antigen (anti-human leukocyte antigen antibodies). All control group infants showed normal values of leukocytes, erythrocytes and platelets at birth. We could not find statistically significant differences of leukocytes, platelets, erythrocytes or hemoglobin values between the two infant groups.
In addition, no statistically significant differences of liver and kidney function test were observed between the two groups (Table 3) .
ECGs
All study group infants had an ECG at birth, 39 at 1 month, 17 at 3 months, 26 at 6 months and 26 at 12 months of life. Forty-five control group infants had an ECG at birth and 30 at 12 months of life.
Mean values of heart rate, PR interval and QTc in the two groups are summarized in Tables 4 and 5 .
No infant showed sinus bradycardia at birth. Heart rate values at birth were similar in the two groups. Five (9.8%) out of 51 infants
Infants from mothers with anti-SSA/Ro antibodies M Motta et al from anti-SSA/Ro-positive mothers (study group) showed a first-degree AVB at birth (PR interval higher then 0.14 s on day 4); of these, four infants were anti-SSA/Ro-positive. In control group, no infant showed AVB at birth. Incidence of first-degree AVB at birth was significantly higher in study than control group infants (P ¼ 0.023). Differences of mean PR interval values at birth were not statistically significant in the two groups. In two of the five infants with first-degree AVB, the PR interval normalized during the first year of life. In the other three, the AVB remained stable. One of these infants that was anti-SSA/Ro-positive, had also a QT prolongation at birth (QTc, 0.462 s).
Three out of 51 study group infants (5.9%) had a QT interval prolongation (QTc higher than 0.440 s) at birth; of these, two infants were anti-SSA/Ro-positive. In control group, two infants (4%) had a QT interval prolongation. The incidence of QT interval prolongation and the QTc values at birth were not significantly different between the two groups. All infants with a QT interval prolongation at birth, from the two groups, showed QT interval normalization within the first 6 weeks of life.
No significant differences of mean heart rate, PR and QTc intervals were observed at 12 months of life. 
Infants from mothers with anti-SSA/Ro antibodies M Motta et al
The correlation between the PR and the QTc interval values at birth was significant in study group (r ¼ 0.3279; P ¼ 0.0188), whereas no significant correlation was found in control group (r ¼ 0.1581; P ¼ 0.3718).
Discussion
In this study, the observation of five infants with a first-degree AVB at birth seems to suggest that the CCHB is the final stage of a gradually developing damage of the conduction tissue, starting in utero. In agreement with other reports, we believe that the natural evolution of a first-degree AVB does not always lead to more advanced disease. Indeed, this condition may remain stable without progression or may recovery with subsequent complete normalization. 17 This finding may have an important consequence for the treatment during pregnancy of the autoimmune-associated congenital heart block with fluorinated steroids, due to the potential risk for both mother and fetus. Although we found five infants with a first-degree AVB in the study group, the PR interval values were similar in the two groups. The reason why only some of the infants who are exposed to the autoantibodies effect develop the atrioventricular node damage is not clear. As observed by Buyon et al., 26 the presence of the anti-SSA/Ro is necessary, although not sufficient to explain this complex mechanism. The involved factors may be several and probably act in the uterine environment during fetal life as our results show the heart block remained stable or recovered during the first year of life. Infants from mothers with anti-SSA/Ro antibodies M Motta et al
In our study sinus bradycardia was not clinically apparent, suggesting a lack of sinoatrial nodal involvement in contrast to the atrioventricular node.
In two previous studies of Cimaz et al. 13 and Gordon et al., 14 a QTc interval prolongation has been described. On the contrary, in a large controlled study of Costedoat-Chalumeau et al. 27 on the electrocardiographic variations in children from anti-SSA/Ropositive mothers, no difference in the QTc interval between the study and control groups were observed. As suggested by CostedoatChalumeau, discrepancies among QTc findings might be explained by the lack of close matching between the study and control groups in previous studies. Indeed, during this period, the QTc interval meet a wide variation, physiologically lengthening from birth to the second month of life. 28 In our study, the times of ECG evaluation were well defined and matched between the two groups. The QTc mean value of infants born from anti-SSA/Ro-positive mothers was slightly prolonged as compared with the control group, although the difference was not significant. Interestingly, a positive correlation between the PR and the QTc interval values in infants from anti-SSA/Ro-positive mothers was found at birth; moreover, in these infants, a shortening of the QTc values from birth to the first and third month of life was observed, at variance with the physiological course. 17 For these reasons, we cannot exclude a marginal interference of the anti-SSA/Ro antibodies transplacental passage on the repolarization of the ventricles.
A possible bias in our study may be introduced by the difference of treatment between the two groups of mothers. Indeed, a higher number of anti-SSA/Ro-positive mothers received hydroxychloroquine (HCQ) during pregnancy, as compared with the control group. Among the side effects of this antimalarial drug, in adults sporadically cases of AVB and histological signs of myocardium toxicity were reported. 29 Interestingly, one patient who developed an AVB after exposure to HCQ was a 40-year-old systemic lupus erythematosus (SLE) woman carrying also anti-SSA/Ro antibodies. 30 To our knowledge, ECG abnormalities have never been reported in infants from mothers treated with HCQ during pregnancy. It is probable that some infants presenting ECG abnormalities and included in the above-mentioned studies were born from mothers taking HCQ during gestation, although such possibility was not specified by the authors. [11] [12] [13] [14] [15] [16] 27 In our study, on the whole, nine infants showed ECG abnormalities at birth (four AVB, four QT prolongations and one AVB with QT prolongation); of these infants, two with the AVBs were born from anti-SSA/Ropositive mothers taking HCQ during pregnancy. The remaining seven infants with conduction disturbances were from mothers not treated with HCQ, five with and two without anti-SSA/Ro antibodies. These findings seem to suggest the lack of association between HCQ treatment of mothers during gestation and ECG abnormalities in infants.
In our experience, hematologic abnormalities were less common than in other studies; indeed, we observed only two infants with thrombocytopenia. However, we only checked blood cell count at birth, which may explain the low incidence of thrombocytopenia in our patients. In the study of Cimaz et al.,
9 the highest rate of hematologic abnormalities, 50% of the studied children, was found at 1-2 months of age, rather than at birth, when abnormal values were found in 13% of the infants. This observation suggests that the hematologic abnormalities detected after the neonatal period are probably not strictly related to the anti-SSA/Ro antibodies, and could be linked to other mechanisms. During young infancy, the anemia, which frequently occurs in this period, is usually accompanied by a reactive neutropenia. This phenomenon is well documented in preterm babies. 31 Besides in adult SLE patients, the pathogenesis of blood cell cytopenias is not only related to the anti-SSA/Ro antibodies, but also may be the consequence of several other mechanisms, as recently reported. 32, 33 In a retrospective analysis of the US Research Registry for Neonatal Lupus, 19 (9%) of 219 patients who had NLE also had probable or possible NLE hepatobiliary disease. 10 Three clinical variants of hepatobiliary disease were observed: a severe liver failure presenting during gestation or the neonatal period; a conjugated hyperbilirubinemia with mild or no elevations of aminotransferases, occurring in the first few weeks of life; and a mild elevation of aminotransferases occurring at approximately 2-3 months of life.
In our study, no case of neonatal liver failure or cholestatic hepatitis was documented, and hepatic function tests aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (gGT) were similar in the two groups. However, it should be noted that during perinatal period, it is difficult to differentiate a mild and transient cholestatic hepatitis because during this period these enzymes frequently rise for nonspecific reasons, such as delivery stress and poor feeding during the first days of breast-feeding. Likewise, jaundice is a common condition in neonates and the measurement of conjugated bilirubin may produce higher than normal as a consequence of unconjugated hyperbilirubinemia. Therefore, as our study evaluated liver function only at birth, we may have not been able to recognize a mild and transient cholestatic liver disease.
In conclusion, infants exposed to anti-SSA/Ro autoantibodies had a statistically significant higher incidence of first-degree AVB. Sinus bradycardia was not clinically apparent, suggesting a lack of sinoatrial nodal involvement. A slight difference between the QTc interval values of the two groups was found; however, more data are needed to rule out or to confirm an effect of the anti-SSA/Ro transplacental passage on the ventricular repolarization in infants.
At variance with previous studies, we observed a low frequency of hematologic abnormalities and no cases of hepatobiliary disease.
